ABILIFY ASIMTUFII® (aripiprazole)

ABILIFY ASIMTUFII is a long-acting injectable, now approved by the FDA

ABILIFY ASIMTUFII has received FDA approval as a long-acting injectable for the treatment of schizophrenia in adults and as a maintenance monotherapy treatment of bipolar I disorder in adults

Establish tolerability with oral aripiprazole before initiating therapy. For patients already stable on oral aripiprazole or another oral antipsychotic, after the first injection, continue treatment with the antipsychotic for 14 consecutive days. For more information, see Dosing & Administration in prescribing information.

Please see IMPORTANT SAFETY INFORMATION below, including BOXED WARNING regarding Increased Mortality in Elderly Patients With Dementia-Related Psychosis.

To learn more about ABILIFY ASIMTUFII click here:

Read the press release